Compare ADMA Biologics Inc (ADMA) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs NICE Ltd — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while NICE Ltd trades at $96.93 (market cap $5.88B). The key difference: NICE Ltd is far larger — about 2.8× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | NICE | |
|---|---|---|
Market Cap | $2.13B | $5.88B |
Sector | Health | Technology |
52-Week High | $20.38 | $171.98 |
52-Week Low | $7.60 | $83.15 |
Enterprise Value | $2.20B | $5.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NICE trades at $97.17, up 0.44% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong profitability with a 65.79% gross margin and 17.57% net income margin, while recent news highlights AI platform expansions with Sopra Steria and AWS European Sovereign Cloud deployment (Business Wire, 2026-07-01).
The stock presents a compelling value opportunity with a P/E of 11.53 below sector averages, supported by a $124.88 analyst price target implying 28% upside. Risks include projected net income decline to $530M in 2026 and overbought short-term RSI levels. Wall Street sentiment remains positive with 13 buy ratings and no sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
